Kailera Therapeutics has raised an eye-watering $600 million in Series B financing to take its lead drug for weight loss into pivotal trials, in a further sign of the insatiable investor appetite for ...
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat, in phase 2/3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback